Overview

• Madrigal Q3 revenue rises to $287.3 mln, driven by Rezdiffra demand

• Company reports a net loss for Q3 despite revenue growth

• Madrigal closes global licensing deal with CSPC Pharma for oral GLP-1

Outlook

• Madrigal expects Rezdiffra sales to grow in 2026

• Company plans to start clinical trials for oral GLP-1 in H1 2026

• Rezdiffra patent protection extends to 2045

Result Drivers

• REZDIFFRA DEMAND - Increased demand for Rezdiffra drives Q3 revenue growth to $287.3 mln

• GLOBAL LICENSING DEAL - Madrigal closed a global licensing agreement with CSPC Pharma for an oral GLP-1 receptor agonist

• GERMANY LAUNCH - Madrigal launched Rezdiffra in Germany following European Commission approval

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Madrigal Pharmaceuticals Inc is $524.50, about 21.4% above its November 3 closing price of $412.35

Press Release: ID:nGNX7NCFYf

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)